Iovance Biotherapeutics Inc Revenue Growth Rates (IOVA), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Iovance Biotherapeutics inc   (NASDAQ: IOVA)
 

IOVA's Revenue Growth by Quarter and Year

Iovance Biotherapeutics Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

IOVA Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -
2nd Quarter June 99.31
1st Quarter March 71.43
FY 170.74





IOVA Revenue second quarter 2026 Y/Y Growth Comment
Iovance Biotherapeutics inc reported Revenue surge of 65.66% year on year in the second quarter 2026, to $ 99.31 millions, this is lower than Iovance Biotherapeutics Inc 's recent average Revenue surge of 2002.03%.

Looking into second quarter 2026 results within Biotechnology & Pharmaceuticals industry 28 other companies have achieved higher Revenue growth. While Iovance Biotherapeutics Inc ' s Revenue jump of 65.66% ranks overall at the positon no. 1198 in the second quarter 2026.


IOVA Revenue ( Y/Y Growth %) 2026
 2025 2024 2023
4th Quarter December - 17.75 % 15252.08 % -
3rd Quarter September - 15.2 % 12359.57 % -
2nd Quarter June 65.66 % 92.7 % 12862.5 % -
1st Quarter March 44.83 % 6750 % - -
FY   - 60.59 % 13688.24 % -

Financial Statements
Iovance Biotherapeutics Inc 's second quarter 2026 Revenue $ 99.31 millions IOVA's Income Statement
Iovance Biotherapeutics Inc 's second quarter 2025 Revenue $ 59.95 millions Quarterly IOVA's Income Statement


IOVA Revenue (Quarter on Quarter Growth %)

 2026
 2025 2024 2023
4th Quarter December - 28.62 % 25.84 % 2.13 %
3rd Quarter September - 12.53 % 88.24 % 95.83 %
2nd Quarter June 39.04 % 21.55 % 4220.83 % -
1st Quarter March -17.68 % -33.07 % 50 % -
FY (Year on Year)   - 60.59 % 13688.24 % -


Back to IOVA Growth rate Comparisons >> Back to IOVA Growth rate Comparisons >>


Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #29
Healthcare Sector #218
Overall #1198

Revenue Y/Y Growth Statistics
High Average Low
11070.12 % 2002.03 % 34.29 %
(Mar 31 2025)   (Mar 31 2026)
Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #29
Healthcare Sector #218
Overall #1198
Revenue Y/Y Growth Statistics
High Average Low
11070.12 % 2002.03 % 34.29 %
(Mar 31 2025)   (Mar 31 2026)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Iovance Biotherapeutics Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
4250.49 % 380.31 % -33.07 %
(Jun 30 2024)  


IOVA's II. Quarter Q/Q Revenue Comment
Iovance Biotherapeutics inc achieved in the II. Quarter 2026 below company average Revenue jump of 39.04% quarter on quarter, to $ 99.31 millions.

Although the II. Quarter 2026 Revenue Q/Q growth was lower than the regular , this has been yet encouraging story, as the II. Quarter surge, eclipses the 21.55% growth in the II. Quarter a year ago

Within Biotechnology & Pharmaceuticals industry 11 other companies have achieved higher Revenue quarter on quarter growth. While Iovance Biotherapeutics Inc 's Revenue growth quarter on quarter, overall rank is 296.


Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #12
Healthcare Sector #75
Overall #296
Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #12
Healthcare Sector #75
Overall #296
Revenue Q/Q Growth Statistics
High Average Low
4250.49 % 380.31 % -33.07 %
(Jun 30 2024)  


IOVA's II. Quarter Q/Q Revenue Comment
Iovance Biotherapeutics inc achieved in the II. Quarter 2026 below company average Revenue jump of 39.04% quarter on quarter, to $ 99.31 millions.

II. Quarter 2026 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the 21.55% in the II. Quarter a year ago.

Within Biotechnology & Pharmaceuticals industry 11 other companies have achieved higher Revenue quarter on quarter growth. While Iovance Biotherapeutics Inc 's Revenue growth quarter on quarter, overall rank is 296.


Iovance Biotherapeutics Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending
(Mar 31 2026)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 324.97 $ 285.61 $ 263.50 $ 250.43 $ 241.53
Y / Y Revenue Growth (TTM) 34.55 % 34.29 % 60.6 % 175.62 % 636.99 %
Year on Year Revenue Growth Overall Ranking # 38 # 2 # 2 # 1 # 2
Seqeuential Revenue Change (TTM) 13.78 % 8.39 % 5.22 % 3.68 % 13.56 %
Seq. Revenue Growth (TTM) Overall Ranking # 1198 # 497 # 52 # 16 # 11


Cumulative Revenue growth Comment
Although Iovance Biotherapeutics Inc 's Annual Revenue growth year on year were below company's average 2002.03% , Revenue announced in the Jun 30 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 34.55% year on year, from 34.29% in Mar 31 2026.

Among companies within the Healthcare sector 10 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 2 to 38.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 29
Healthcare Sector # 11
Overall # 38

Revenue TTM Y/Y Growth Statistics
High Average Low
11070.12 %
 2002.03 %
34.29 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 29
Sector # 218
S&P 500 # 1198
Cumulative Revenue growth Comment
Although Iovance Biotherapeutics Inc 's Annual Revenue growth year on year were below company's average 2002.03% , Revenue announced in the Jun 30 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 34.55% year on year, from 34.29% in Mar 31 2026.

Among companies within the Healthcare sector 10 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 2 to 38.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 29
Healthcare Sector # 11
Overall # 38

Revenue TTM Y/Y Growth Statistics
High Average Low
11070.12 %
2002.03 %
34.29 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 29
Sector # 218
S&P 500 # 1198




Other Revenue Growth
Biotechnology & Pharmaceuticals Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
IOVA's Revenue Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue jump for the quarter ending Jun 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2026
Ars Pharmaceuticals Inc 114.15%$ 114.150 millions
Foghorn Therapeutics Inc 112.68%$ 112.677 millions
60 Degrees Pharmaceuticals Inc 106.04%$ 106.044 millions
Mobia Medical Inc 102.35%$ 102.352 millions
Ptc Therapeutics inc 101.55%$ 101.548 millions
Eton Pharmaceuticals Inc 98.63%$ 98.631 millions
Immunitybio inc 93.91%$ 93.907 millions
Syndax Pharmaceuticals Inc 91.76%$ 91.759 millions
Phathom Pharmaceuticals Inc 88.02%$ 88.021 millions
Fennec Pharmaceuticals Inc 85.18%$ 85.184 millions
Alamar Biosciences Inc 82.08%$ 82.075 millions
Seastar Medical Holding Corp81.95%$ 81.953 millions
Sera Prognostics Inc 76.47%$ 76.471 millions
Innovative Eyewear Inc 74.46%$ 74.459 millions
Madrigal Pharmaceuticals Inc 71.17%$ 71.169 millions
Tg Therapeutics Inc 70.27%$ 70.272 millions
Tarsus Pharmaceuticals Inc 69.41%$ 69.406 millions
Hyperfine Inc 67.70%$ 67.698 millions
Alnylam Pharmaceuticals Inc 66.86%$ 66.856 millions
Emergent Biosolutions Inc 66.29%$ 66.288 millions
Vivos Therapeutics Inc 65.69%$ 65.691 millions
Iovance Biotherapeutics inc 65.65%$ 65.654 millions
Billiontoone Inc 64.40%$ 64.403 millions
Anteris Technologies Global Corp 63.27%$ 63.269 millions
Nexgel Inc 63.24%$ 63.242 millions
Carlsmed Inc 59.58%$ 59.575 millions
Sonoma Pharmaceuticals Inc 59.55%$ 59.552 millions
Arcutis Biotherapeutics Inc 59.33%$ 59.331 millions
Nephros Inc 58.55%$ 58.551 millions
Bioadaptives Inc 54.95%$ 54.955 millions


About Iovance Biotherapeutics Inc Revenue Growth Rates (IOVA), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Iovance Biotherapeutics Inc (CIK 1425205).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001104659-26-091716
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Iovance Biotherapeutics Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.